13 June 2017 - The Department of Health has asked NICE to produce guidance on the use inotuzumab ozogamicin in the NHS in England for the treatment of patients with relapsed or refractory acute lymphoblastic leukaemia.

Inotuzumab ozogamicin is not recommended for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults.

Inotuzumab ozogamicin will be considered at a second appraisal committee meeting on 12 July 2017.

Read NICE Appraisal Consultation Document